We are a well-rounded, multidisciplinary team with extensive backgrounds in microbiology, immunology, operations, marketing, and business development.
Emily Stein, PhD
Chief Executive Officer and BOD member
Emily Stein embraces the entrepreneurial spirit, having co-founded several biotechnology start-ups. She brings a unique scientific background that spans molecular biology, microbiology and molecular and cellular immunology. She completed her Post-Doctoral Fellowship in the Department of Immunology & Rheumatology at Stanford University where she studied the role of the neuroendocrine-immune axis in rheumatic disease. Dr. Stein holds a PhD in Microbiology from the University of California at Berkeley where she studied signaling pathways involved in stress response and community development in bacteria and received her B.S. in Microbiology and Immunology at the University of Iowa where she studied the interaction between M. tuberculosis and innate immune cells.
Susanne Szabo, PhD
Vice President of Research and Development
Susanne Szabo has over 20 years of experience in creating and leading successful R&D programs in autoimmune diseases, inflammation and the microbiome. She has managed local and global cross-functional teams in academic, biotech and large pharmaceutical settings by focusing on her core values of integrity, scientific rigor and teamwork. Dr. Szabo has made significant scientific and medical contributions that are published in a number of patents and journals such as Cell, Science, and Immunity. During her post-doctoral Fellowship at Harvard Medical School/School of Public Health, she identified T-bet as a critical factor in T helper cell development and earned a Ph.D. in Immunology at Washington University where she studied cytokine receptor signal transduction pathways.
William Robinson, PhD
Advisor and Co-founder
Bill Robinson is a co-founder of Primal Therapies, Inc. and Atreca, a privately held biotechnology company developing novel therapeutics based on a deep understanding of the human immune response. He’s also currently an Associate Professor of Medicine in the Department of Immunology and Rheumatology at Stanford University. Dr. Robinson is also the the Director of the Stanford Osteoarthritis Initiative and a co-lead of the Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus Network of the NIH. He and his laboratory members invented the technology underlying Atreca’s Immune Repertoire Capture™ technology. Dr. Robinson is an inventor on twenty-one patent applications, and technologies developed in his Stanford and VA laboratories have been licensed to seven companies in the biotechnology industry. He received his BS, MD, and PhD degrees from Stanford University and completed his clinical training in internal medicine at the University of California, San Francisco.
Vice President of Corporate Development
Lindsey Huff earned her master’s degree in business and marketing from the University of San Francisco. She has 12+ years of experience in planning, executing, and evaluating strategic marketing initiatives in the consumer and B2B sectors. She has led marketing, branding, and business development initiatives with various sized businesses, ranging from start-ups to Fortune 500 companies. Ms. Huff’s experience in these areas, plus her proven track record of establishing and maintaining long-term business relationships, will help to build and execute on Primal Therapies’ business strategy.
Kirk has spent >16 years building ISO/FDA compliant Quality Systems for start-ups in the medical device space and is very experienced in ISO13485 manufacturing standards, which will be heavily leveraged at Primal. Kirk will also provide internal auditing functions for the company. His other functions will include streamlining the documentation system to provide superior connectivity to meet our partners’ needs. Kirk’s previous experience includes (Medtronic, Covidien, SpineAlign Medical, Cordis, Boston Scientific). Kirk holds an MBA from Case Western and a BS in Mechanical Engineering from Case Institute of Technology.
The Board of Directors
We have recruited experienced and multi-disciplined Directors to serve as guide posts for the operational team and overall company. All of the Directors are successful entrepreneurs with relevant start-up experience and have a track record of successfully scaling corporate growth.
Lisa has >30 years of biotech experience, exemplified by her own entrepreneurial endeavors (MyoScience Inc.) and the numerous start-ups and larger companies for which she has held C-level and Director positions (CryoVascular Systems Inc., MicroHeart Inc., Catheter Innovations Inc., Johnson & Johnson Inc. and Haemonetics Inc.). Significant to the company, Lisa has also held numerous operational and process engineering roles, in addition to her business development and product marketing and sales experience, Lisa’s wisdom can translate across all operational and commercial needs for the company. Lisa’s adaptive and strategic mind, combined with her previous Board experience and adeptness in financial management and prioritization make her a value-add to the Primal team. Lisa holds degrees in applied science and technology from Rochester Institute of Technology, MBA from University of Massachusetts and University of Miami.
Dr. Peter French
Peter has >18 years of scientific and biotech commerce experience and has also engaged in several entrepreneurial endeavors (BCAL Diagnostics, Cryosite Ltd). Peter has held C-level and Director positions at numerous companies, including taking several through the IPO process (Probiomics Ltd, Benitec Biopharma Ltd, Confidential Pathology, Ausdiagnostics PTY Ltd) and a NASDAQ listing. Significant to Primal, Peter not only has years of successful fundraising and investor relations experience, he has a gifted scientific mind and is familiar with both consumer goods and biopharmaceutical business models. We are impressed by his integrity and his keen desire to conduct international business in a mutualistic manner that reflects the values of the Primal team. Peter sits on several Boards and his experience will be a tremendous value add in the Boardroom and to the R&D team. Peter holds a PhD in cell and molecular biology and MBA from Deakin University and a MSc in carcinogenesis and BSc in zoology and microbiology from University of Sydney.
Joelle is also an entrepreneur who bucked the system and has designed, built and operates an impressive private equity group called Area One Farms, to solve for unmet needs in the agriculture space. Joelle is ambitious and possesses both depth and breadth spanning multiple markets. Aside from her robust problem solving capability, Joelle is very successful at financial and stakeholder management. She has a diverse background ranging from chemical engineering, financial markets and commerce, to business and law. Joelle is a Rhoades Scholar, receiving a BA in Jurisprudence (Oxford University) and is a Biodesign Fellow and Fulbright Scholar (Stanford University) where she received her Master of Law degree. Her foundational background is in chemical engineering at University of Western Ontario and in Business Administration at Ivey School of Business.